Huma, a MedTech company based in London, has raised £62 million in its Series D round of financing. Huma aims to revolutionize healthcare by connecting physicians and patients and moving from a reactive to proactive approach to medicine. The company has also developed a cloud platform that uses generative AI integrations, which can speed up the process of launching digital health products to meet regulatory requirements from years to days. This platform offers a range of features, including regulated disease management tools configuration, a library of pre-built modules, device connectivity, APIs and integration, diagnostic and predictive AI algorithms, and a marketplace for digital-first care and research.
The funds raised in the Series D round brought the total issuance of shares by Huma to over $80 million, bringing its total funding to over $300 million. Both new and existing investors participated in the round, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures, Leaps by Bayer, and others. HSBC Bank acted as an advisor for Huma during the fundraise.
Huma’s technology has been used in over 3,000 hospitals and clinics, with 35 million individuals already screened, and 1.8 million active users across its products in over 70 countries. Additionally, Huma collaborates with more than half of the top 20 pharmaceutical companies globally and has participated in significant national healthcare projects around the world.
Dan Vahdat, CEO and founder of Huma, expressed his gratitude for the support of new and existing shareholders and their contributions towards fulfilling the company’s vision. He likened Huma Cloud Platform to Shopify, except it is for digital health instead of eCommerce. Digital and AI advancements, according to Vahdat, can be scaled and made affordable for everyone, enabling proactive medicine and a smoother transition from reactive medicine.
